PKMYT1, a potential ‘Achilles heel’ of treatment resistant ER+ breast cancers with the poorest prognosis

KIPA profiling reveals druggable kinase expression levels induced by ESR1-TAFs in T47D breast cancer cells. Credit: Molecular Cancer Therapeutics (2024). DOI: 10.1158/1535-7163.MCT-23-0564 Up to 80% of breast cancer deaths occur in patients with tumors that express estrogen receptor-alpha. Although these estrogen receptor-positive (ER+) breast cancers often initially respond to standard treatment that combines endocrine therapies with CDK4/6 inhibitors, drug resistance often develops leading to lethal metastatic disease that spreads from the breast and does not respond to available treatments. Looking to identify new vulnerabilities in this type of cancer that Read More